Condition: Diabetic Kidney Disease · Chronic Kidney Diseases · Sponsor: Prokidney
The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).
This description comes directly from the study's public registry record.
Beth Hilburger · 336-999-7031 · info@prokidney.com
Always discuss trial participation with your own doctor first.
| Boise Kidney & Hypertension Institute | Meridian, Idaho, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05918523